Literature DB >> 32360823

Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission.

Anne B Hu1, William Tan1, Vikram Deshpande2, Ashwin N Ananthakrishnan3.   

Abstract

BACKGROUND & AIMS: Goals of treatment for Crohn's disease (CD) are clinical and endoscopic remission. It is not clear whether histologic markers of healing associate with endoscopic remission in patients with CD.
METHODS: We identified patients with CD from a single institutional registry, and collected data from 129 patients (46.5% female; mean age 25 y; mean CD duration 14.5 y) who underwent colonoscopy evaluation and had simple endoscopic scores for CD below 3 (the definition of endoscopic remission). Histologic signs of CD activity were graded in 192 biopsies (90 ileum and 102 colon), and disease was classified as active (presence of crypt destruction, neutrophils, erosions or ulcerations), quiescent (presence of architectural distortion and chronic inflammatory infiltrate), or normal histology (none of these). The primary outcome was clinical relapse within 2 y (dose escalation, change in therapy, need for systemic steroids, or CD-related hospitalization or surgery). We performed multivariable regression adjusting for relevant confounders to examine the independent predictive value of histologic activity.
RESULTS: Within 2 y of endoscopic evaluation, 42 patients (32.6%) had a clinical relapse. There were no significant differences in proportions of patients with active ileal CD (23.8%), quiescent CD (28.6%), or normal histology (37%) between those who relapsed and those remaining in remission (P = .43). There were no significant differences in proportions of relapses among patients with active colonic disease (38.1%), quiescent disease (35.0%), or normal histology (27.9%, P = .73). A linear regression analysis found no association between histologic features of active disease in ileal histology biopsies and symptom scores (Harvey Bradshaw index and simple inflammatory bowel disease questionnaire scores).
CONCLUSIONS: In an analysis of biopsies from patients with CD who had achieved clinical and endoscopic remission, histologic remission was not associated with clinical relapse within 2 years.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; IBD; Outcome; Prognostic Factor

Year:  2020        PMID: 32360823     DOI: 10.1016/j.cgh.2020.04.050

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  5 in total

1.  A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data.

Authors:  Jordan E Axelrad; Michael C Sachs; Jonas F Ludvigsson; Ola Olén
Journal:  Clin Epidemiol       Date:  2020-10-09       Impact factor: 4.790

2.  Can visceral adipose tissue and skeletal muscle predict recurrence of newly diagnosed Crohn's disease in different treatments.

Authors:  Zinan Zhang; Xiaoyu Yu; Ning Fang; Xiuyan Long; Xixian Ruan; Jianing Qiu; Sifan Tao; Pan Gong; Kai Nie; An Li; Xiaoyan Wang; Li Tian
Journal:  BMC Gastroenterol       Date:  2022-05-18       Impact factor: 2.847

3.  Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission.

Authors:  Hyuk Yoon; Sushrut Jangi; Parambir S Dulai; Brigid S Boland; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Inflamm Bowel Dis       Date:  2021-07-27       Impact factor: 5.325

Review 4.  Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art.

Authors:  Edoardo Vespa; Ferdinando D'Amico; Mauro Sollai; Mariangela Allocca; Federica Furfaro; Alessandra Zilli; Arianna Dal Buono; Roberto Gabbiadini; Silvio Danese; Gionata Fiorino
Journal:  J Clin Med       Date:  2022-02-11       Impact factor: 4.241

5.  Interleukin-26 Expression in Inflammatory Bowel Disease and Its Immunoregulatory Effects on Macrophages.

Authors:  Dongjuan Song; Lijie Lai; Juntao Lu; Jinlu Tong; Zhihua Ran
Journal:  Front Med (Lausanne)       Date:  2022-04-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.